Objectives: The aims of this study were to identify optimal quantitative breast magnetic resonance imaging background parenchymal enhancement (BPE) parameters associated with breast cancer risk and compare performance to qualitative assessments.
B
reast cancer is the second leading cause of cancer-related deaths in women. Early detection with screening mammography reduces patient mortality, [1] [2] [3] [4] and its value persists in microsimulation models, even with modern advances in treatment. 5 However, mammography performs less well in some subsets of women, particularly those who are at higher-than-average lifetime risk. 6, 7 Accordingly, the American Cancer Society recommends screening breast magnetic resonance imaging (MRI) in addition to mammography in women with greater than 20% lifetime risk of developing breast cancer. 8 Precise determination of an individual's breast cancer risk to inform eligibility for breast MRI and risk-reducing strategies is a challenge. Currently, breast cancer risk assessments are reliant on models that weigh factors common in the general population, such as family history and hormonal exposures. 9, 10 Furthermore, although these clinical models are helpful at predicting risk at the population level, they are less accurate in estimating which individual woman will develop breast cancer.
Imaging markers of breast cancer risk may be capable of augmenting clinical risk assessments. It is well established that mammographic density is associated with elevated breast cancer risk; however, clinical incorporation of this imaging parameter using qualitative systems such as the American College of Radiology Breast Imaging Reporting and Data System has been challenging because of interobserver variability. 11, 12 Qualitative background parenchymal enhancement (BPE) assessment, based on visual assessment of the amount and intensity of normal tissue enhancement on dynamic contrast-enhanced (DCE) MRI, holds promise as a more accurate imaging feature to refine breast cancer risk assessments. [13] [14] [15] However, visual assessments of BPE are subjective and also prone to interobserver and intraobserver variability. Thus, the development of a robust approach to objectively measure the amount of fibroglandular tissue (FGT), a correlate to mammographic breast density, and BPE levels on MRI could lead to better integration of these markers into individual breast cancer risk assessments. [16] [17] [18] [19] With this goal, we developed a semiautomated magnetic resonance image-processing tool to quantitatively measure a variety of FGT and BPE characteristics. 20 Using a case-control cohort of high-risk patients who underwent screening breast MRI, we aimed to identify and optimize quantitative parameters associated with risk of developing breast cancer. Furthermore, we sought to compare the degree of association of these quantitative parameters with future breast cancer diagnosis versus standard qualitative BPE assessments.
MATERIAL AND METHODS

Study Population
In this institutional review board-approved, Health Insurance Portability and Accountability Act-compliant study, we used a case-control matched cohort that comprised 23 women with a breast cancer (invasive cancer or ductal carcinoma in situ) diagnosed at any time point after screening MRI and 23 women who did not have breast cancer diagnosed by the time of our tumor registry query. These 1:1 case-control pairs were identified from a total of 487 asymptomatic women who underwent high-risk screening breast MRI from January 2006 through December 2011 at our institution. Women in the cohort were 18 years or older with no personal history of breast cancer but considered high risk because of having a genetic mutation (or untested first-degree relative) such as BRCA1 or BRCA2, a genetic syndrome (eg, Li-Fraumeni or Cowden syndrome), a history of chest irradiation at younger than 30 years, or a greater than 20% lifetime risk based on a clinical model that incorporates family history (eg, Tyrer-Cuzick). In the case of a single subject having multiple high-risk screening MRI examinations during the study period, only the earliest (index) examination was included. After identifying the 23 women in our case group, potential control cases were identified from the remaining 464 women who did not receive a diagnosis of breast cancer during the study period. The 1:1 case-control matching was achieved by randomly selecting a negative control case, matched both with age and BRCA mutation status, while maximizing MRI follow-up time for the negative control subjects. In the cancer cohort, time to diagnosis was defined as the time from index MRI to the date of biopsy that led to the cancer diagnosis. In the control cohort, follow-up time was defined as the time of index MRI to the time of tumor registry inquiry performed September 30, 2013.
MRI Technique
Two MRI scanning protocols were used during our study period: one from January 2006 to January 2010 performed on a 1.5-T GE Signa LX scanner (GE Healthcare, Waukesha, Wis) and the second from January 2010 to December 2011 performed on a 3-T Philips Achieva TX scanner (Philips Healthcare, Best, the Netherlands). Both MRI protocols were in compliance with the American College of Radiology breast MRI accreditation program guidelines. 21 For both protocols, imaging was performed in the axial plane and included precontrast and at least 2 postcontrast T1-weighted fat-suppressed 3-dimensional (3D) fast spoiled gradient recalled acquisitions. Gadolinium contrast material (Omniscan; GE Healthcare) was power injected (0.1 mmol/kg at 2 mL/s) followed by a 20-mL saline flush for all examinations. All examinations were processed using a computer-aided evaluation system (CADstream; Merge Healthcare, Chicago, Ill) and reviewed on high-resolution picture archiving and communication system monitors.
For the 1.5-T protocol, an 8-channel dedicated breast coil (Sentinelle; Invivo, Gainesville, FL) was used, and DCE was acquired with the following parameters: repetition time/echo time, 5.5/2.7 milliseconds; flip angle, 10°; field of view, 32 to 38 cm; 0.85 Â 0.85 mm in-plane, slice thickness, 1.6 mm; and matrix size, 420 Â 420. For the 3-T protocol, a 16-channel dedicated breast coil (Mammotrak; Philips Healthcare) was used, and DCE was acquired with the following parameters: repetition time/echo time, 5.9/3.0 milliseconds; flip angle, 10°; field of view, 22 to 33 cm; 0.5 Â 0.5 mm in-plane, slice thickness, 1.3 mm; and matrix size, 440 Â 660. Scan time was approximately 180 seconds per acquisition for both 1.5 and 3-T, with initial contrast-enhanced acquisition centered between 90 and 110 seconds after contrast material administration.
MRI Quantification
Background parenchymal enhancement quantification was performed using customized software developed in MATLAB (Mathworks, Natick, Mass). On the DCE series, a single slice of 1 breast at or near the level of the nipple, felt to be most representative of the patient's FGT, was selected for analysis by a radiologist (HR) with 8 years of radiology experience, blinded to outcomes. In patients who had suspicious findings described on the MRI in 1 breast, the contralateral breast was used for quantification. A research scientist with 2 years of experience in quantitative breast magnetic resonance analysis was trained to perform the segmentation. First, whole breast area was calculated by segmenting the breast using a semiautomated edge extraction algorithm with manual definition of the chest wall (Fig. 1A) . Next, an automated threshold was applied to the precontrast DCE image to segment FGT from adipose tissue within the whole breast area. The FGT boundary was then manually refined to exclude the nipple and large vessels from the FGT calculation (Fig. 1B) . The FGT area was calculated from the segmentation, as well as the ratio of the FGT area to whole breast area.
Background parenchymal enhancement maps were generated by calculating the percent enhancement (PE) for each voxel within the FGT
where S 0 and S 1 are the signal intensity on the precontrast and first postcontrast DCE images, respectively. Background parenchymal enhancement maps were generated for varying PE thresholds, specifically, 10%, 20%, 30%, 40%, 50%, 60%, and 70%, where only voxels equal to or greater than the minimum threshold were included in the map (Fig. 2) . Higher thresholds could not be reliably assessed because of the limited number of voxels meeting the enhancement criteria in many of the women. A total of 10 quantitative parameters were calculated for each BPE map, including BPE area (in mm 2 ), BPE area-to-FGT area ratio, BPE intensity statistics (25th percentile, median, 75th percentile, mean, SD, skewness, and kurtosis), and integrated intensity (BPE area multiplied by mean BPE intensity [in mm 2 ]). If no voxels met the given threshold, the area and integrated intensity parameters were defined as 0. For the remaining BPE intensity statistics, values were considered missing if there were not at least 5 voxels meeting the given threshold.
Qualitative BPE assessment was performed at the time of the clinical interpretation using the American College of Radiology Breast Imaging Reporting and Data System, fourth edition, criteria. 22 The 4 categories of BPE are as follows: 1 = minimal, 2 = mild, 3 = moderate, and 4 = marked. 
Statistical Analysis
The Wilcoxon signed rank test was used to compare the quantitative BPE parameters at each PE threshold between the cancer and control cohorts. Matched pairs were excluded from a comparison if the parameter could not be calculated at a given threshold because of an insufficient number of enhancing voxels. Each of the 10 BPE parameters was optimized by selecting the PE threshold that resulted in the largest Wilcoxon signed rank test statistic (ranging from 0 = no difference to 1 = difference in all pairs) for cancer versus control cohorts, with the smaller threshold chosen in the case of a tie. P values for each BPE metric were adjusted for multiple comparisons using a 2-stage approach: A permutation-based step-down method was first used to account for testing 7 thresholds, 23 followed by Holm method to account for testing 10 parameters.
Receiver operator characteristic (ROC) curve analysis and the area under the ROC curve (AUC) were used to assess performance of the optimized quantitative BPE parameters to discriminate between cancer and control cohorts in comparison with qualitative BPE categorization. The bootstrap was used to adjust AUC estimates to account for optimizing the BPE parameters using the same data set 24 and to compute confidence intervals (CIs) using the percentile method.
25 Spearman rank correlation coefficient was used to examine relationships between the qualitative and quantitative BPE parameters. All statistical analyses were performed using R (version 3.1.1; R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
The cancer cohort included 23 women who developed breast cancer at any time point after the screening breast MRI (mean age, 47.7 ± 10 years; 6 patients with BRCA mutations). The control cohort comprised women matched 1:1 for age and BRCA status while maximizing follow-up time (mean, 5.6 ± 1.3 years; range, 2.4-7.0 years) ( Table 1) . In 5 cases, the cancer and control subjects were imaged at different field strengths (1 cancer subject at 1.5-Twith control at 3-T, 4 cancer subjects at 3-Twith control subjects at 1.5-T).
Identification of Optimal Enhancement Thresholds for BPE Parameters
First, the identification of optimal enhancement thresholds for each BPE parameter was performed by comparing the quantitative BPE parameters at each threshold between cancer and control cohorts. Performance of the quantitative BPE parameters at each PE threshold is shown in Figure 3 , and comparison of each optimized metric between cases and control subjects is shown in Table 2 . Optimal PE thresholds were 50% for BPE area and area ratio, 40% for BPE integrated intensity, and ranged from 10% to 30% for BPE intensity parameters (other than skew and kurtosis). Based on the optimized thresholds, all quantitative BPE parameters were significantly higher in cancer cases than in matched control subjects after accounting for the number of comparisons except for BPE skewness and kurtosis (adjusted P > 0.99 for both). Results were not affected by excluding the 5 case-control pairs imaged using different field strengths.
As shown in Figure 3 , each BPE metric tended to have similar performance over a range of PE thresholds, although performance also tended to drop off at low or high thresholds. Background parenchymal enhancement integrated intensity was relatively less sensitive to the PE threshold as its rank correlation ranged from 0.64 to 0.74 when the enhancement threshold ranged from 10% to 40% (P = 0.13).
Association of Optimized Quantitative MRI Parameters With Breast Cancer Risk
A comparison of the matched cancer and control cohorts was then performed using the optimized thresholds for the quantitative BPE parameters. Among the BPE area parameters, BPE area (AUC = 0.78) had the highest estimated AUC, although the AUC for BPE area ratio was similar (AUC = 0.76, Table 2 ). The 25th percentile of BPE intensity (AUC = 0.77) had the highest AUC among BPE intensity parameters, although most of these parameters had comparable AUCs between 0.75 and 0.77. Background parenchymal enhancement integrated intensity, a combination of area and mean BPE, had an AUC of 0.78, similar to the best area-based and intensity-based parameters.
Whole breast area (P = 0.89), FGT area (P = 0.29), and FGT area-to-whole breast area ratio (P = 0.39) were not significantly different between cancer cases and control subjects ( Table 2 ). The qualitative assessment of BPE had an AUC of 0.70 (95% CI, 0.57-0.83; Table 2 ), as reported in a prior study. 13 Although numerically higher, the AUCs for quantitative BPE parameters of BPE area, 25th percentile, and integrated intensity were not significantly higher than those of qualitative BPE assessment (P = 0.10, P = 0.62, and P = 0.08, respectively). The ROC curves for each are shown in Figure 4 .
Correlation Between Quantitative and Qualitative BPE Parameters
Correlation of each quantitative BPE parameter at the optimized threshold with qualitative assessments was then performed. At their optimized PE thresholds, most of the quantitative BPE parameters were significantly correlated with the qualitative BPE categorization (Table 3) . Background parenchymal enhancement integrated intensity (ρ = 0.72, P < 0.001) and area (ρ = 0.71, P < 0.001) had the highest correlation with the qualitative BPE category, whereas the other BPE intensity parameters had more moderate correlation coefficients between 0.58 and 0.64 (P < 0.001 for each).
Substantial correlation was observed between the different threshold-optimized quantitative BPE parameters. Background 13 †Mean ± SD with range in parenthesis. ‡Data are time to cancer diagnosis in the cancer cohort and follow-up time in the control cohort. 
DISCUSSION
We examined a wide range of quantitative breast MRI BPE parameters in women undergoing high-risk breast cancer screening and found that increased BPE area, BPE-to-FGT area ratio, and BPE intensity were each significantly associated with the development of breast cancer, whereas quantitative precontrast breast tissue MRI parameters, including FGT area and whole breast area, were not. This suggests that the optimized BPE parameters identified may allow for more sophisticated risk models that combine clinical features with quantitative breast MRI metrics. Although these quantitative BPE parameters demonstrated numerically larger AUCs for association of breast cancer diagnosis than qualitatively assessed BPE, the AUC differences were not found to be statistically significant. This suggests that qualitative BPE parameters may provide a reasonable stratification of breast cancer risk in clinical practice, despite their subjective nature, although a larger study is needed to more definitively compare the performance of qualitative and qualitative BPE parameters. Previous studies regarding interobserver variability in qualitative BPE assessment showed fair agreement overall. With training (2-hour presentation), there was sustained improvement in interobserver variability to moderate agreement. 18 Our study further builds on prior studies validating semiautomated and fully automated software in quantitatively evaluating BPE compared with qualitative assessment. 17, 26 Tagliafico et al   17 used a manually selected threshold value to separate enhancing from nonenhancing breast tissue and showed that the semiautomated software they used had better intraobserver and interobserver correlation in quantifying BPE than qualitative assessments. With a semiautomated 3D tool, Ha et al 26 found statistically significant positive correlation between quantitative and qualitative BPE assessments at different BPE threshold values. In addition to validation of our semiautomated quantification tool, our study found additional BPE measures that were correlated to qualitative BPE assessments and associated with increased breast cancer risk. These tools hold promise in incorporating quantitative assessment of BPE into future breast cancer risk assessment models because of the nonsubjective assessment and potential for integration into existing software for interpreting breast MRI such as computeraided diagnosis systems.
Our study did not find any statistically significant associations between MRI measurements of FGT, the MRI correlate to mammographic breast density, and breast cancer development. These findings agree with other studies that qualitative MRI assessments of amount of FGT do not correlate with breast cancer development in this high-risk group of women. 13, 27 Given the previously established correlation of breast density with breast cancer development, it is interesting that neither qualitative nor quantitative MRI correlates of breast density were significantly associated with breast cancer in this population, suggesting that mammographic density/FGT is a relatively weak risk factor for breast cancer development in women already determined to be at higher risk than the average population. This limited relationship with breast cancer risk in the high-risk population is supported by a previously published study, which showed that in women with a BRCA gene mutation, adding mammographic breast density did not improve breast cancer risk assessment. 28 With the optimized thresholds for each parameter, both BPE area and intensity parameters had comparable performance to qualitative assessment in predicting breast cancer risk. However, Cases and control subjects were pooled together for calculations (ie, n = 46).
